Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Growth resistance and resilience of mixed silver fir and Norway spruce forests in central Europe: Contrasting responses to mild and severe droughts.
Bottero A, Forrester DI, Cailleret M, Kohnle U, Gessler A, Michel D, Bose AK, Bauhus J, Bugmann H, Cuntz M, Gillerot L, Hanewinkel M, Lévesque M, Ryder J, Sainte-Marie J, Schwarz J, Yousefpour R, Zamora-Pereira JC, Rigling A. Bottero A, et al. Glob Chang Biol. 2021 Sep;27(18):4403-4419. doi: 10.1111/gcb.15737. Epub 2021 Jun 24. Glob Chang Biol. 2021. PMID: 34166562 Free PMC article.
Growth and resilience responses of Scots pine to extreme droughts across Europe depend on predrought growth conditions.
Bose AK, Gessler A, Bolte A, Bottero A, Buras A, Cailleret M, Camarero JJ, Haeni M, Hereş AM, Hevia A, Lévesque M, Linares JC, Martinez-Vilalta J, Matías L, Menzel A, Sánchez-Salguero R, Saurer M, Vennetier M, Ziche D, Rigling A. Bose AK, et al. Among authors: bottero a. Glob Chang Biol. 2020 Aug;26(8):4521-4537. doi: 10.1111/gcb.15153. Epub 2020 Jun 8. Glob Chang Biol. 2020. PMID: 32388882 Free PMC article.
Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study.
Ozen A, Chongsrisawat V, Sefer AP, Kolukisa B, Jalbert JJ, Meagher KA, Brackin T, Feldman HB, Baris S, Karakoc-Aydiner E, Ergelen R, Fuss IJ, Moorman H, Suratannon N, Suphapeetiporn K, Perlee L, Harari OA, Yancopoulos GD, Lenardo MJ; Pozelimab CHAPLE Working Group. Ozen A, et al. Lancet. 2024 Feb 17;403(10427):645-656. doi: 10.1016/S0140-6736(23)02358-9. Epub 2024 Jan 23. Lancet. 2024. PMID: 38278170 Clinical Trial.
77 results